Integer Holdings Corporation Securities Class Action Deadline February 9, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Lawsuit Reminder: ClaimsFiler alerts investors that those who purchased Integer shares between July 25, 2024, and October 22, 2025, must file lead plaintiff applications by February 9, 2026, to participate in the securities class action lawsuit and protect their rights.
- Earnings Warning Impact: On October 23, 2025, Integer lowered its full-year 2025 sales guidance to between $1.840 billion and $1.854 billion, significantly below analyst expectations, resulting in a 32% drop in share price from $109.11 to $73.89 in one day, reflecting concerns over market adoption of its products.
- Legal Liability Allegations: The lawsuit alleges that Integer and certain executives failed to disclose material information during the class period, violating federal securities laws, which could lead to severe legal consequences and impact the company's reputation and future financing capabilities.
- Investor Support Platform: ClaimsFiler offers a free shareholder information service to assist investors in timely submitting claims, ensuring they can recover losses from securities class action settlements, highlighting the importance of protecting retail investor rights.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 85.540
Low
75.00
Averages
93.38
High
140.00
Current: 85.540
Low
75.00
Averages
93.38
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
